HALO
Price:
$49
Market Cap:
$6.23B
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to...[Read more]
Industry
Biotechnology
IPO Date
2004-03-16
Stock Exchange
NASDAQ
Ticker
HALO
According to Halozyme Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Dividend Yield is 0%. This represents a change of -100.00% compared to the average of 0.07% of the last 4 quarters.
The mean historical Dividend Yield of Halozyme Therapeutics, Inc. over the last ten years is 0%. The current 0% Dividend Yield has changed 0% with respect to the historical average. Over the past ten years (40 quarters), HALO's Dividend Yield was at its highest in in the December 2019 quarter at 7.43%. The Dividend Yield was at its lowest in in the December 2014 quarter at 0%.
Average
0%
Median
0%
Minimum
0%
Maximum
0%
Discovering the peaks and valleys of Halozyme Therapeutics, Inc. Dividend Yield, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual Dividend Yield = 0%
Minimum Annual Increase = 0%
Minimum Annual Dividend Yield = 0%
Year | Dividend Yield | Change |
---|---|---|
2023 | 0% | 0% |
2022 | 0% | 0% |
2021 | 0% | 0% |
2020 | 0% | 0% |
2019 | 0% | 0% |
2018 | 0% | 0% |
2017 | 0% | 0% |
2016 | 0% | 0% |
2015 | 0% | 0% |
2014 | 0% | 0% |
The current Dividend Yield of Halozyme Therapeutics, Inc. (HALO) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
0%
5-year avg
0%
10-year avg
0%
Halozyme Therapeutics, Inc.’s Dividend Yield is less than Agios Pharmaceuticals, Inc. (0%), less than Insmed Incorporated (0%), less than Cerevel Therapeutics Holdings, Inc. (0%), less than Ultragenyx Pharmaceutical Inc. (0%), less than BioMarin Pharmaceutical Inc. (0%), less than Seagen Inc. (0%), less than Alnylam Pharmaceuticals, Inc. (0%), less than Exelixis, Inc. (0%), less than Alector, Inc. (0%), less than Legend Biotech Corporation (0%), less than Ascendis Pharma A/S (0%), less than Cytokinetics, Incorporated (0%), less than Edgewise Therapeutics, Inc. (0%), less than Apellis Pharmaceuticals, Inc. (0%), less than Blueprint Medicines Corporation (0%), less than BeiGene, Ltd. (0%), less than Inhibrx Biosciences, Inc. (6.04%), less than Protagonist Therapeutics, Inc. (0%), less than DICE Therapeutics, Inc. (0%), less than Larimar Therapeutics, Inc. (0%), less than Viridian Therapeutics, Inc. (0%),
Company | Dividend Yield | Market cap |
---|---|---|
0% | $3.18B | |
0% | $13.09B | |
0% | $8.19B | |
0% | $4.36B | |
0% | $12.25B | |
0% | $43.15B | |
0% | $31.59B | |
0% | $10.17B | |
0% | $385.85M | |
0% | $7.51B | |
0% | $7.76B | |
0% | $5.79B | |
0% | $3.05B | |
0% | $3.83B | |
0% | $5.98B | |
0% | $21.35B | |
6.04% | $203.82M | |
0% | $2.77B | |
0% | $2.27B | |
0% | $393.05M | |
0% | $1.60B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Halozyme Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Halozyme Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Dividend Yield?
How can you use the Dividend Yield?
What is Halozyme Therapeutics, Inc.'s Dividend Yield?
How is the Dividend Yield calculated for Halozyme Therapeutics, Inc. (HALO)?
What is the highest Dividend Yield for Halozyme Therapeutics, Inc. (HALO)?
What is the 3-year average Dividend Yield for Halozyme Therapeutics, Inc. (HALO)?
What is the 5-year average Dividend Yield for Halozyme Therapeutics, Inc. (HALO)?
How does the current Dividend Yield for Halozyme Therapeutics, Inc. (HALO) compare to its historical average?